Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib before reduced-intensity allogeneic stem cell transplantation for myelofibrosis
NL-OMON47477Phase 2Completed
- Sponsor
- HOVON
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pacritinib in myelofibrosis (MF), primary myelofibrosis (PMF) and post-polycythemia vera myelofibrosis (PPV-MF), sponsored by HOVON. Started Jul 2018; status: completed.
02
Drugs
pacritinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on NL-OMON47477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47477.